PDF(Pubmed)
Abstract：
UNASSIGNED: There is an unmet need for biomarkers to identify patients with axial spondyloarthritis (axSpA). Increasing evidence suggest the presence of autoantibodies in a subset of axSpA patients. The aim of this study was to identify novel IgA antibodies in early axSpA patients and to determine their diagnostic potential in combination with previously determined IgG antibodies against UH (Hasselt University)-axSpA-IgG antigens.
UNASSIGNED: An axSpA cDNA phage display library constructed from axSpA hip synovium, was used to screen for novel IgA antibodies in plasma from early axSpA patients. The presence of these antibodies against novel UH-axSpA-IgA antigens was determined in two independent axSpA cohorts, in healthy controls and in patients with chronic low back pain.
UNASSIGNED: We identified antibodies to 7 novel UH-axSpA-IgA antigens, of which 6 correspond to non-physiological peptides and 1 to the human histone deacetylase 3 (HDAC3) protein. IgA antibodies against 2 of these 7 novel UH-axSpA-IgA antigens and IgG antibodies against 2 of the previously identified antigens were significantly more present in early axSpA patients from the UH cohort (18/70, 25.7%) and the (Bio)SPAR cohort (26/164, 15.9%), compared to controls with chronic low back pain (2/66, 3%). Antibodies to this panel of 4 antigens were present in 21.1% (30/142) of patients with early axSpA from the UH and (Bio)SPAR cohorts. The positive likelihood ratio for confirming early axSpA using antibodies to these 4 UH-axSpA antigens was 7.0. So far, no clinical correlation between the novel identified IgA antibodies and inflammatory bowel disease could be identified.
UNASSIGNED: In conclusion, screening an axSpA cDNA phage display library for IgA reactivity resulted in the identification of 7 novel UH-axSpA-IgA antigens, of which 2 show promising biomarker potential for the diagnosis of a subset of axSpA patients, in combination with previously identified UH-axSpA-IgG antigens.
UNASSIGNED: An axSpA cDNA phage display library constructed from axSpA hip synovium, was used to screen for novel IgA antibodies in plasma from early axSpA patients. The presence of these antibodies against novel UH-axSpA-IgA antigens was determined in two independent axSpA cohorts, in healthy controls and in patients with chronic low back pain.
UNASSIGNED: We identified antibodies to 7 novel UH-axSpA-IgA antigens, of which 6 correspond to non-physiological peptides and 1 to the human histone deacetylase 3 (HDAC3) protein. IgA antibodies against 2 of these 7 novel UH-axSpA-IgA antigens and IgG antibodies against 2 of the previously identified antigens were significantly more present in early axSpA patients from the UH cohort (18/70, 25.7%) and the (Bio)SPAR cohort (26/164, 15.9%), compared to controls with chronic low back pain (2/66, 3%). Antibodies to this panel of 4 antigens were present in 21.1% (30/142) of patients with early axSpA from the UH and (Bio)SPAR cohorts. The positive likelihood ratio for confirming early axSpA using antibodies to these 4 UH-axSpA antigens was 7.0. So far, no clinical correlation between the novel identified IgA antibodies and inflammatory bowel disease could be identified.
UNASSIGNED: In conclusion, screening an axSpA cDNA phage display library for IgA reactivity resulted in the identification of 7 novel UH-axSpA-IgA antigens, of which 2 show promising biomarker potential for the diagnosis of a subset of axSpA patients, in combination with previously identified UH-axSpA-IgG antigens.
摘要：
未经证实：对识别轴性脊柱关节炎（axSpA）患者的生物标志物的需求尚未满足。越来越多的证据表明axSpA患者亚组存在自身抗体。这项研究的目的是在早期axSpA患者中鉴定新型IgA抗体，并结合先前确定的针对UH（HasseltUniversity）-axSpA-IgG抗原的IgG抗体确定其诊断潜力。
未经授权：从axSpA髋关节滑膜构建的axSpAcDNA噬菌体展示文库，用于筛选早期axSpA患者血浆中的新型IgA抗体。在两个独立的axSpA队列中确定了针对新型UH-axSpA-IgA抗原的这些抗体的存在，在健康对照组和慢性腰背痛患者中。
未经证实：我们鉴定了7种新型UH-axSpA-IgA抗原的抗体，其中6对应于非生理肽，1对应于人组蛋白脱乙酰酶3（HDAC3）蛋白。针对这7种新的UH-axSpA-IgA抗原中的2种的IgA抗体和针对2种先前鉴定的抗原的IgG抗体在UH队列（18/70，25.7％）和（Bio）SPAR队列（26/164，15.9％）的早期axSpA患者中明显更多。与慢性下腰痛对照组相比（2/66，3％）。在来自UH和(Bio)SPAR队列的21.1%(30/142)的具有早期axSpA的患者中存在针对该组4种抗原的抗体。使用针对这4种UH-axSpA抗原的抗体确认早期axSpA的阳性似然比为7.0。到目前为止,未发现新鉴定的IgA抗体与炎症性肠病之间的临床相关性.
未经批准：总而言之，筛选axSpAcDNA噬菌体展示文库的IgA反应性，鉴定出7种新的UH-axSpA-IgA抗原，其中2显示了诊断axSpA患者子集的有希望的生物标志物潜力，与先前鉴定的UH-axSpA-IgG抗原组合。
未经授权：从axSpA髋关节滑膜构建的axSpAcDNA噬菌体展示文库，
未经证实：我们鉴定了7种新型UH-axSpA-IgA抗原的抗体，
未经批准：总而言之，
